Search

Your search keyword '"Kim, S. -J"' showing total 197 results
Start Over Author "Kim, S. -J" Publisher wiley
197 results on '"Kim, S. -J"'

1. IBRUTINIB PLUS BR OR R‐CHOP IN PREVIOUSLY TREATED PATIENTS WITH FOLLICULAR OR MARGINAL ZONE LYMPHOMA: THE PHASE 3 SELENE STUDY

Author

Nastoupil, L. J., primary, Hess, G., additional, Pavlovsky, M. A., additional, Danielewicz, I., additional, Freeman, J., additional, García‐Sancho, A. M., additional, Glazunova, V., additional, Grigg, A., additional, Hou, J., additional, Janssens, A., additional, Kim, S. J., additional, Masliak, Z., additional, McKay, P., additional, Merli, F., additional, Munakata, W., additional, Nagai, H., additional, Özcan, M., additional, Preis, M., additional, Wang, T., additional, Zhu, J., additional, Rowe, M., additional, Qin, R., additional, Henninger, T., additional, Curtis, M., additional, Caces, D. B., additional, Thieblemont, C., additional, and Salles, G., additional

Published
2023
Full Text
View/download PDF

2. Ibrutinib in Combination with Ifosfamide, Etoposide, and Rituximab Followed by Ibrutinib Maintenance Therapy in Patients with R/R‐PCNSL: A Multicenter Phase II Study

Author

Choi, Y. S., primary, Song, G., additional, Baek, D. W., additional, Yoon, S. E., additional, Kang, K., additional, Yhim, H., additional, Oh, S. Y., additional, Jeong, S. H., additional, Kim, S. J., additional, Kim, H. J., additional, Do, Y. R., additional, and Yang, D., additional

Published
2023
Full Text
View/download PDF

4. An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study

Author

Romano, M. R., Parolini, B., Allegrini, D., Mickalewska, Z., Adelman, R., Bonovas, S., Bopp, S., Citirik, M., Tekin, K., Fiser, I., Boon, C. J. F., Van, D., Donvito, G., Gungel, H., Ozdogan Erkul, S., Unsal, E., Osmanbasoglu, O., Dincer, N., Ercalik, N. Y., Yenerel, N. M., Amar, J. -P., Ennemoser, A., Besozzi, G., Sallam, A. A. B., Ellabban, A. A., Chang, W., Eandi, C. M., Demir, M., Lee, J., Pak, K., Arrevola, L., Sloka, A., Morawski, K., Kulig - Stochmal, A., Romanowska - Dixon, B., Striebe, N. -A., Feltgen, N., Hoerauf, H., Inan, U. U., Tanev, I., Dyrda, A., Schuler, A., Lucke, K., Brix, A., Pape, S., Kusserow-Napp, C., Loo, P. A., Kanra, A. Y., Ardagil Akcakaya, A., Ari Yaylali, S., Bae, S. H., Kim, H. K., Kim, S. J., Han, J. R., Nam, W. H., Odrobina, D., Lavaque, E., Bertelli, E., Coser, S., Ziemssen, F., Forlini, M., Benatti, C., Cavallini, G. M., Stefanickova, J., Berrod, J. -P., Saksonov, S., Lytvinchuk, L., Moussa, M., Stefaniotou, M., Christodoulou, E., Zayed, M. A., Oz, O., Tassinari, P., Koch, P., Declercq, C., Johnston, R., Rusnak, S., Penas, S., Ozdek, S., Ucgul, Y., Cisiecki, S., Dziegielewski, K., Klimczak, D., Michalewska, Z., Michalewski, J., Nawrocka, Z., Nawrocki, J., Ornafel, K., Pikulski, Z., Maciej, M., Acar, N., Elshafei, M. M., Hamon, F., Soyeur, R., Badat, I., Brousseau, B., Hermouet, E., Peiretti, E., Lee, J. -H., Ferreira, N., Yoon, H. -S., Alkhars, W. I., Dudani, A., Minu, R., Telang, O., Morepatil, V. G., Furtado, M. J., Y. -J., Jo, Piccolino, F. C., Finzi, A., Ophthalmology, and Amsterdam Neuroscience - Complex Trait Genetics

Subjects
Pars plana, medicine.medical_specialty, Visual acuity, medicine.medical_treatment, Vitrectomy, 03 medical and health sciences, 0302 clinical medicine, PDT, Ophthalmology, medicine, central serous chorioretinopathy, First episode, Aspirin, Univariate analysis, medicine.diagnostic_test, business.industry, General Medicine, Fluorescein angiography, eye diseases, laser, Serous fluid, medicine.anatomical_structure, 030221 ophthalmology & optometry, medicine.symptom, business, 030217 neurology & neurosurgery, medicine.drug
Abstract

Purpose: To study and compare the efficacy of different therapeutic options for the treatment of central serous chorioretinopathy (CSCR). Methods: This is a nonrandomized, international multicentre study on 1719 patients (1861 eyes) diagnosed with CSCR, from 63 centres (24 countries). Reported data included different methods of treatment and both results of diagnostic examinations [fluorescein angiography and/or optical coherent tomography (OCT)] and best-corrected visual acuity (BCVA) before and after therapy. The duration of observation had a mean of 11 months but was extended in a minority of cases up to 7 years. The aim of this study is to evaluate the efficacy of the different therapeutic options of CSCR in terms of both visual (BCVA) and anatomic (OCT) improvement. Results: One thousand seven hundred nineteen patients (1861 eyes) diagnosed with CSCR were included. Treatments performed were nonsteroidal anti-inflammatory eye drops, laser photocoagulation, micropulse diode laser photocoagulation, photodynamic therapy (PDT; Standard PDT, Reduced-dose PDT, Reduced-fluence PDT), intravitreal (IVT) antivascular endothelial growth factor injection (VEGF), observation and other treatments. The list of the OTHERS included both combinations of the main proposed treatments or a variety of other treatments such as eplerenone, spironolactone, acetazolamide, beta-blockers, anti-anxiety drugs, aspirin, folic acid, methotrexate, statins, vitis vinifera extract medication and pars plana vitrectomy. The majority of the patients were men with a prevalence of 77%. The odds ratio (OR) showed a partial or complete resolution of fluid on OCT with any treatment as compared with observation. In univariate analysis, the anatomical result (improvement in subretinal fluid using OCT at 1 month) was favoured by age 500 μm (p = 0.03). The OR for obtaining partial or complete resolution showed that anti-VEGF and eyedrops were not statistically significant; whereas PDT (8.5), thermal laser (11.3) and micropulse laser (8.9) lead to better anatomical results with less variability. In univariate analysis, the functional result at 1 month was favoured by first episode (p = 0.04), height of subretinal fluid >500 μm (p

Published
2019

6. Management of acute agitation in Hong Kong and comparisons with Australasia

Author

David C. M. Kong, Kim S. J. Lao, Jonathan C Knott, Esther W. Chan, Matthew Sik Hon Tsui, Ian C. K. Wong, Cedric Tang, David Taylor, Gordon C K Wong, Hiu Fai Ho, and Ling-Pong Leung

Subjects
Olanzapine, medicine.medical_specialty, Combination therapy, business.industry, Sedation, Accident and emergency, Alternative medicine, Validated questionnaire, Clinical Practice, Emergency medicine, Emergency Medicine, medicine, Midazolam, medicine.symptom, business, medicine.drug
Abstract

Background Little is known about the use of sedation drugs for the management of acute agitation in Hong Kong's Accident and Emergency Departments (AEDs) and how it compares with Australasian practice. Objective The aim of this study was to determine drug preferences, clinicians' perceived confidence in management, barriers/gaps in training and perceived usefulness of existing clinical practice guidelines (CPGs) in Hong Kong. Method A validated questionnaire was used, with case vignettes typical of patients presenting to AEDs with acute agitation. The questionnaire was distributed by hand to all trainees and fellows of the Hong Kong College of Emergency Medicine (HKCEM). Two reminders were sent. Results Of 483 HKCEM members, 280 (58.0% [95% CI 53.5–62.3]) responded. For monotherapy, 46.8% (95% CI 41.0–52.6) of respondents chose haloperidol to manage the undifferentiated patient, followed by midazolam (33.9%, 95% CI 28.6–39.7) and diazepam (13.9%, 95% CI 10.4–18.5). Most respondents (83.6%, 95% CI 78.8–87.5) would not administer combination therapy. Respondents were confident in managing agitation overall. The lack of local/institutional CPGs (55.7%, 95% CI 49.9–61.4) was perceived as an important barrier. Institutional guidelines were considered the most useful CPGs (66.4%, 95% CI 60.7–71.7). Most respondents (72.9%, 95% CI 67.4–77.7) perceived a HKCEM endorsed CPG would be useful. Conclusion Haloperidol and benzodiazepines are frequently used as monotherapy for the management of acute agitation in Hong Kong's AEDs. Management in Hong Kong differs from Australasian practice in that combination therapy is less common and clinicians' choice of sedation drugs are less variable overall. Results suggest that future work on CPG development and training regarding the safe use of combination therapy would be well received.

Published
2015

38. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea

Author

Kim, Y. S., primary, Kim, S. J., additional, Yoon, J. H., additional, Suk, K. T., additional, Kim, J. B., additional, Kim, D. J., additional, Kim, D. Y., additional, Min, H. J., additional, Park, S. H., additional, Shin, W. G., additional, Kim, K. H., additional, Kim, H. Y., additional, and Baik, G. H., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results